Compare CZNC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CZNC | CBIO |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.4M | 471.3M |
| IPO Year | 2009 | N/A |
| Metric | CZNC | CBIO |
|---|---|---|
| Price | $22.85 | $17.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $23.50 | ★ $26.67 |
| AVG Volume (30 Days) | 70.8K | ★ 326.5K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | $1,139.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $8.72 |
| 52 Week High | $24.25 | $27.41 |
| Indicator | CZNC | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 46.33 |
| Support Level | $21.28 | $17.02 |
| Resistance Level | $24.01 | $19.13 |
| Average True Range (ATR) | 0.61 | 1.23 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 51.96 | 34.84 |
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.